✦ LIBER ✦

From chemical to drug: neurodegeneration drug screening and the ethics of clinical trials

✍ Scribed by Heemskerk, Jill; Tobin, Allan J.; Ravina, Bernard

Book ID: 109941282
Publisher: Nature Publishing Group
Year: 2002
Tongue: English
Weight: 80 KB
Volume: 5
Category: Article
ISSN: 1097-6256
DOI: 10.1038/nn931

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical Trials of Drugs and Vaccines Am

Clinical Trials of Drugs and Vaccines Among the Desperately Poor in Poor Nations: Ethical Challenges and Ethical Solutions

✍ Caplan, A L 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 68 KB

Drug Testing and the Right to Privacy: A

Drug Testing and the Right to Privacy: Arguing the Ethics of Workplace Drug Testing

✍ Michael Cranford 📂 Article 📅 1998 🏛 Springer 🌐 English ⚖ 83 KB

From Darkness to Light With Biomarkers i

From Darkness to Light With Biomarkers in Early Clinical Trials of Cancer Drugs

✍ Carden, CP; Banerji, U; Kaye, SB; Workman, P; de Bono, JS 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 122 KB

From Trial and Error to Trial Simulation

From Trial and Error to Trial Simulation. Part 1: The Importance of Model-Based Drug Development for Antidepressant Drugs

✍ Santen, G; van Zwet, E; Danhof, M; Della Pasqua, O 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 497 KB

From Adverse Drug Reactions to Drug Disp

From Adverse Drug Reactions to Drug Disposition to WHO and Essential Medicines to Our Discipline of Clinical Pharmacology

✍ Reidenberg, M M 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 88 KB 👁 1 views

French recommendations for clinical drug

French recommendations for clinical drug trials in cognitive disorders of the elderly

✍ Dr. Bernard Michel; Roland Sambuc; Jean-Claude Scotto 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 449 KB 👁 2 views

## Abstract A consensus conference on the topic of clinical drug trials in cognitive disorders of the elderly was held in Marseille on January 28–29, 1993. At the end of this conference, several recommendations were made. Drugs used in trials must be chosen according to solid neurobiological eviden